Date: November 28<sup>th</sup> 2022

Your Name:\_\_\_Cecilia Beatrice Chighizola

# Manuscript Title:\_ FLUCTUATION OF ANTI-DOMAIN 1 AND ANTI-β2 GLYCOPROTEIN I ANTIBODY TITERS OVER TIME IN PATIENTS WITH PERSISTENTLY POSITIVE ANTIPHOSPHOLIPID ANTIBODIES

Manuscript number (if known): ar-22-1268

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
Ũ	pending		
	P		
9	Participation on a Data	None	
5	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	Werfen	Provided APS Action with kits for testing of aPL through
	materials, drugs, medical		an unrestricted grant – there was no involvement of
	writing, gifts or other		Werfen in the design of this study, analysis of the data
	services		and/or preparation of this manuscript
13	Other financial or non-	None	
	financial interests		

Date:\_\_\_\_\_\_28/11/2022\_\_\_\_\_\_ Your Name:\_\_\_\_\_FRANCESCA PREGNOLATO\_\_\_\_\_\_

Manuscript Title:\_ FLUCTUATION OF ANTI-DOMAIN 1 AND ANTI-β2 GLYCOPROTEIN I ANTIBODY TITERS OVER TIME IN PATIENTS WITH PERSISTENTLY POSITIVE ANTIPHOSPHOLIPID ANTIBODIES

Manuscript number (if known): ar-22-1268


In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
Ũ	pending		
	P		
9	Participation on a Data	None	
5	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	Werfen	Provided APS Action with kits for testing of aPL through
	materials, drugs, medical		an unrestricted grant – there was no involvement of
	writing, gifts or other		Werfen in the design of this study, analysis of the data
	services		and/or preparation of this manuscript
13	Other financial or non-	None	
	financial interests		



In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertain to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other ite the time frame for disclosure is the past 36 months.

> Name all entities with whom you have this

Specifications/Comments (e.g., if payments were made to you or to your

		relationship or indicate none (add rows as needed)	institution)
-		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	Research from hom
3	Royalties or licenses	None	Drogillion tunding Tleeney
1	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	None	Semble pr Bristall-Meyerro Non Related Subject
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	Member of Rheamotology Society State of Sand Poulo of Society State
11	Stock or stock options	None	- ACTION Alliance (un point)
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

-

Please place an "X" next to the following statement to indicate your agreement:

rlo

Date:	_26 Nov 2022	2
	_	

Your Name: Maria Tektonidou\_\_\_

# Manuscript Title:\_ FLUCTUATION OF ANTI-DOMAIN 1 AND ANTI-β2 GLYCOPROTEIN I ANTIBODY TITERS OVER TIME IN PATIENTS WITH PERSISTENTLY POSITIVE ANTIPHOSPHOLIPID ANTIBODIES

Manuscript number (if known): ar-22-1268

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
_		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	Neree	
6	Payment for expert testimony	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
	incerings and/or traver		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
11			
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Date:\_\_\_\_\_NOVEMBER 26, 2022\_\_\_\_\_

Your Name:\_\_\_\_Vittorio Pengo\_\_\_\_\_

# Manuscript Title:\_ FLUCTUATION OF ANTI-DOMAIN 1 AND ANTI-β2 GLYCOPROTEIN I ANTIBODY TITERS OVER TIME IN PATIENTS WITH PERSISTENTLY POSITIVE ANTIPHOSPHOLIPID ANTIBODIES

Manuscript number (if known): ar-22-1268

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	Werfen Group, Milan, Italy	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	Werfen	Provided APS Action with kits for testing of aPL through
	materials, drugs, medical		an unrestricted grant – there was no involvement of
	writing, gifts or other		Werfen in the design of this study, analysis of the data
	services		and/or preparation of this manuscript
13	Other financial or non-	None	
15	financial interests		

Date: 28-11-2022

Your Name: Guillermo Ruiz-Irastorza

# Manuscript Title:\_ FLUCTUATION OF ANTI-DOMAIN 1 AND ANTI-β2 GLYCOPROTEIN I ANTIBODY TITERS OVER TIME IN PATIENTS WITH PERSISTENTLY POSITIVE ANTIPHOSPHOLIPID ANTIBODIES

Manuscript number (if known): ar-22-1268

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	x_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	xNone	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	Neree	
6	Payment for expert testimony	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
	incerings and/or traver		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
11			
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

·	inhahi	/		DISCLOSURE FORM		
Date:	1/20/1				······································	
Your Name:	Ĥ.	MIChael	19191	<u>ON</u> [		-

# Manuscript Title:\_ FLUCTUATION OF ANTI-DOMAIN 1 AND ANTI-β2 GLYCOPROTEIN I ANTIBODY TITERS OVER TIME IN PATIENTS WITH PERSISTENTLY POSITIVE ANTIPHOSPHOLIPID ANTIBODIES

Manuscript number (if known): ar-22-1268

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	<u> </u>	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		· · · · · · · · · · · · · · · · · · ·	
		Time frame: past	36 months
2	Grants or contracts from	<u>None</u>	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	V None	
		V	

					a 151		· · · ·	
<u> </u>			·····	····				
4	Consulting fees	None None						
5	Payment or honoraria for	X None						
-	lectures, presentations,	- <del></del>					·	
	speakers bureaus,			· · · · · ·				
	manuscript writing or						· · · · ·	
								· · ·
	educational events					<u> </u>	a'? * .	
6	Payment for expert	<u>X</u> None						<b>.</b> .
ļ	testimony							
		~						
.7	Support for attending	XNone						3
	meetings and/or travel		- • • · · ·	÷.,	н.,	<sup>.</sup> .		
:					· ·			
			•		4			
· . ,		,			• .	· .		· · · · ·
	- 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1	1			,	· .		
8	Patents planned, issued or	X None				·		
_	pending							
	pending							
	Destisionation and a Data	V Name				··· ,		
9	Participation on a Data	None None		4.1			100 100 100 100 100 100 100 100 100 100	
	Safety Monitoring Board or							
	Advisory Board	1			· · · · · · · · · · · · · · · · · · ·		1	
10	Leadership or fiduciary role	<u>X</u> _None					_	
	in other board, society,	V						
	committee or advocacy							-
	group, paid or unpaid							
11	Stock or stock options	X None					and the second second	
1 11			ale o			<u>- Hurris II. († 1900)</u> 1940 - D. M. Karl	<u> </u>	
					•		· · · · · · · · · · · · · · · · · · ·	
		· · · · · · · · · · · · · · · · · · ·	i		· · · · · · · · · · · · · · · · · · ·		· · · · · · · · · · · · · · · · · · ·	
12	Receipt of equipment,	X_None						
	materials, drugs, medical							
	writing, gifts or other							
	services							
13	Other financial or non-	X None						
<b></b>	financial interests			, ,				
							· · · · · · · · · · · · · · · · · · ·	

Date: November 30<sup>th</sup> 2022

Your Name:\_\_\_Maria Gerosa

# Manuscript Title:\_ FLUCTUATION OF ANTI-DOMAIN 1 AND ANTI-β2 GLYCOPROTEIN I ANTIBODY TITERS OVER TIME IN PATIENTS WITH PERSISTENTLY POSITIVE ANTIPHOSPHOLIPID ANTIBODIES

Manuscript number (if known): ar-22-1268

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
Ũ	pending		
	P		
9	Participation on a Data	None	
5	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	Werfen	Provided APS Action with kits for testing of aPL through
	materials, drugs, medical		an unrestricted grant – there was no involvement of
	writing, gifts or other		Werfen in the design of this study, analysis of the data
	services		and/or preparation of this manuscript
13	Other financial or non-	None	
	financial interests		

Date:\_\_\_\_November 29, 2022\_\_\_\_\_

Your Name:\_\_\_Paul R Fortin \_\_\_\_\_\_

# Manuscript Title:\_ FLUCTUATION OF ANTI-DOMAIN 1 AND ANTI-β2 GLYCOPROTEIN I ANTIBODY TITERS OVER TIME IN PATIENTS WITH PERSISTENTLY POSITIVE ANTIPHOSPHOLIPID ANTIBODIES

Manuscript number (if known): ar-22-1268

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	Please see attached for list of peer-review and public funding agencies from Lupus Canada, Canadian Rheumatology Association, Canadian Institutes of Health Research, the Arthritis Society (Canada), Sociétés interconseils (Canada), COVID-19 Immunity Task Force (Canada), Kidney Foundation of Canada

3	Royalties or licenses	X None	
Э	Royalties of licenses		
4	Consulting fees	X None	
4	consulting lees		
5	Payment or honoraria for	None	One presentation sponsored by AstraZanasa on unmat
5	lectures, presentations,		One presentation sponsored by AstraZeneca on unmet needs in lupus
	speakers bureaus,		One presentation on treatment of lupus sponsored by
	manuscript writing or		GSK
	educational events		
6	Payment for expert	X None	
0	testimony		
	cestimony		
7	Support for attending	X None	
,	meetings and/or travel		
8	Patents planned, issued or	None	Methods and Kits for Diagnosing Systemic Autoimmune
	pending		Rheumatic Diseases. Patents #: PCT/CA2022/050849.
			Quebec. Fortin P, Boilard E, Becker Y. V/Réf. : n/a - N/Réf.: 000819-0436
			N/Rel. 000819-0430
9	Participation on a Data	None	AstraZeneca Lupus Advisory Board
9	Safety Monitoring Board or		GSK Lupus Advisory Board
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

2. Grants or contracts from any entity (if not indicated in item #1 above).			
2022-2023	<b>Co-Investigator.</b> <i>Megakaryocyte: a new player in systemic lupus erythematosus.</i> Lupus Fondation of America, Inc. (USA) / 2022 Lupus Canada Catalyst Grant. 40,000 CAD <b>PI</b> : Éric Boilard		
2022-2024	<b>Co-Investigator</b> . <i>Personalized therapy in lupus pregnancies</i> . Canadian Rhuematology association (CRA). 114,000 CAD <b>PI</b> : Ann Elaine Clarke. <b>Co-Investigator</b> : Bernatsky S, Touma Z, Grunbaum A, Hanly J, Peschken C, Laskin C, Costedoat N, Urowitz M, Proulx L.		
2022-2027	<b>Co-Investigator</b> . Impact of vascular injury derived exosomes in Lupus Nephritis. Canadian Institutes of Health Research (CIHR). 577,575 CAD PI: Mélanie Dieudé. Co-Investigator: Éric Boilard, Héloise Cardinal		
2022-2023	<b>Co-Principal Investigator.</b> Booster dose of mRNA SARS-CoV-2 vaccine versus non mRNA vaccine for people living with systemic autoimmune rheumatic deseases without adequate humoral response post standard mRNA vaccination. Canadian Institutes of Health Research (CIHR). 995.312 CAD. <b>CO-PI</b> : Gaston De Serres, Ines Colmegna. <b>co-investigators:</b> Bazin R, Dionne M, Hudson M, Bernatsky S, Finzi A, Kaufmann D, Bourré-Tessier J, Flamand L, Libman M, Dieudé M, Goard C, Mendel A.		
2022-2023	<b>Co-Investigator</b> . <i>Co-developing a fLexible cAre delivery model for Rheumatic InflammaTorY diseases</i> . CIHR Planning & Dissemination Grant –ICS (Winter 2022). 20,000 CAD.		
	<b>PI</b> : Diane Lacaille, <b>co-investigators</b> : Bansback N, Barber C, Barnabe C, Bartlett S, Da Costa, Hazlewood G, Hoens A, Koehn C, Li L, Oelke N.Patient Partners: Collins J (APAB), Gervais F (PIRA). Collaborators: Au D, Bardi M, Bessette L, Caron M, Eastwood C, Kur J, MacMullan P, Patrick P, Shojania K.		
2022-2025	<b>Co-Investigator.</b> <i>FcgRI as a potential therapeutic target in inflammatory arthritis.</i> Arthritis Society Strategic Operating Grant competition. PI: Marc POULIOT		
2021-2022	<b>Co-Principal Investigator</b> . COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases. Ministère de la Santé et des Services Sociaux (MSSS). 808,000 CAD.		
2021 – 2023	<b>Co-Investigator.</b> The UNIversité Laval SARS-CoV-2 variant Research Network (UNICORN). Secrétariat Inter-Conseils (Canada) (CRSH, CRSNG, IRSC). 100,000 CAD [Grant] PI: Louis Flamand, co-investigators: Marc Brisson, Vincent Raymond, Denis Leclerc, Mariana Baz, Paul R. Fortin, Eric Boilard, Nicolas Flamand, Marc Pouliot, Ève Dubé, Yannick Doyon.		
2021 – 2022	<b>Co-Investigator.</b> Safety immUnogenicity of Covid-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED).		

	COVID-19 Immunity Task Force. 3,187,905 CAD [Grant]
	PI: Sasha Bernatsky, co-investigators: Vinod Chandran, Dawn Bowdish, Carol Hitchon, Anne-Claude GINGRAS, Nigil Haroon, Robert Inman, Richard Cook, Gilaad Kaplan, Allison McGeer, Vincent Piguet, Proton Rahman, Mark Silverberg, Tania Watts, Bindee Kuriya, Stephanie Garner, Maggie Larché, John Marshall, Ishac Nazy, Antonio Avina-Zubieta, Cheryl Barnabe, Gilles Boire, Ines Colmegna, Glen Hazelwood, Diane Lacaille, Jessica Widdifield, Karen Colwill, Heidi Wood.
2020 – 2025	<b>Co-Principal Investigator.</b> Platelets and neutrophils: the two culprits mediating pain in inflammatory arthritis. Canadian Institutes of Health Research. 910,350 CAD [Grant]
	PI: Éric Boilard, co-investigators: Clémence Belleannée, Steeve Lacroix
2020 – 2023	<b>Principal Investigator.</b> The impact of antimalarial drugs in arthritis patients exposed to SARS-CoV-2-the CoVIRAL project. The Arthritis Society. COVID-20-001. 300,000 CAD [Grant]
	Co- Principal Investigators: Eric Boilard, Deborah Da Costa
2020 – 2023	<b>Co-Principal Investigator.</b> Platelets and neutrophils: The two culprits mediating pain in inflammatory arthritis. The Arthritis Society. 360,000 CAD [Grant] Declined due to overlap with CIHR.
	PI: Éric Boilard, co-applicants: Yotis Senis, Clémence Belleannée, Steve Lacroix, Louis Bessette
2020 – 2023	<b>Collaborator.</b> Impact of the autoimmune anti-LG3 response on Lupus Nephritis. Kidney foundation of Canada.180,000 CAD [Grant]
	PI: Mélanie Dieudé, Co-applicant: Heloise Cardinal, Collaborators: Eric Boilard, Marie Josee Hebert, Joyce Rauch
2020 – 2022	<b>Collaborator.</b> Work disability and function in systematic lupus erythematosus: a national mixed-methods sequential explanatory study. Canadian Initiative for Outcomes in Rheumatology cAre. 117, 098 CAD [Grant]
	PI: Behdin Nowrouzi-Kia, Zahi Touma
2019 – 2022	<b>Principal Investigator.</b> Mapping anti-mitochondrial antibodies in systemic lupus erythematosus. Canadian Institutes of Health Research. 416,280 CAD [Grant]

Date:\_\_26 November 2022\_\_\_\_\_

Your Name:\_\_\_D. Ware Branch, MD\_\_\_\_\_

# Manuscript Title:\_ FLUCTUATION OF ANTI-DOMAIN 1 AND ANTI-β2 GLYCOPROTEIN I ANTIBODY TITERS OVER TIME IN PATIENTS WITH PERSISTENTLY POSITIVE ANTIPHOSPHOLIPID ANTIBODIES

Manuscript number (if known): ar-22-1268

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated in item #1 above).	TNF-alpha Blockade with Certolizumab to Prevent Pregnancy Complications in High-Risk Patients with APS NIH/NIAMS R21AR21069189- 03S1	Payments made to institution

Rei: Co-Principal Investigator (with 0r. 12 Samon, ND)  Payments made to institution    3  Royalties or licenses  X  Payments made to institution    3  Royalties or licenses  X  None    4  Consulting fees  None  Payment made to me    5  Payment or honoraria for reducational events  Payment made to me  Payment made to me    5  Payment or honoraria for reducational events  Consulting or collection of the patients of the patients of antiprospheric patients  Payment made to me    6  Payment or honoraria for educational events  Grand Rounds, University of antiprospheric patients. October 2004/20220.  Payment made to me    6  Payment or honoraria for educational events  Grand Rounds, University of antiprospheric patients. October 2004/20220.  Payment made to me    7  Support for attending or educational events  Grand Rounds, University of antiprospheric patients of antiprospheric patients of antiprospheric patients of the patients May 20, 2004/2004/2004/2004/2004/2004/2004/2004				
Image: Construction of Constructions in High-Rise Patients with APS of SLE      Payments made to institution        3      Royalties or licenses      X      None        4      Consulting fees      None      Payment made to me        5      Payment or honoraria for lectures presentations, speakers bureaus, manuscript writing or educational events      None      Payment made to me        5      Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events      None      Payment made to me        5      Payment or honoraria for lectures presentations, speakers bureaus, manuscript writing or educational events      None      Payment made to me        6      Payment controversies, American Society for Clinical Laboratory Service Region of Mathematic Distribution Service Region of Mathematic Distribution Service Region Service Region Vill American Society for Clinical Laboratory Service Region Vill American Society for Clinical Laboratory Service Region Service Region Vill American Society for Clinical Laboratory Service Region Vill American Society for Clinical Laboratores A 2021.      Payment made to me        6      Payment for expert testimony      Corand Rundis, University of Payment made to me      Payment made to me        7 <td></td> <td></td> <td></td> <td></td>				
Image: Second				
Role: Principal Investigator      3    Royalties or licenses			Certolizumab to Prevent Pregnancy Complications in High-Risk Patients with APS	Payments made to institution
3    Royalties or licenses   None      4    Consulting fees   None      5    Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events    Payment made to me      5    Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events   None      6    Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events   None      7    Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events   None      0    Grand Rounds, University of lognosis, treatment, controversite. American Society for Cinital, Labotarby Service Region VIII Annual Seminar, October 27, 2020    Payment made to me      0    Resemble Accord Rounds, Cornell University Monore. A fate of there patients May 26, 2021    Payment made to me      1    Grand Rounds, Cornell University Of New York, Stonytore, A tale of three patients May 26, 2021    Payment made to me      2    Grand Rounds, University of New York, Stonytore, November 3, 2021    Payment made to me      1    Mone    Swason, Martin & Bell medical expert consultancy    Payment made to me      2    Mone    Swason, Martin & Bell medical expert consultancy    Payment made to me      1 <t< td=""><td></td><td></td><td></td><td></td></t<>				
4    Consulting fees    None      4    Consulting fees    None      5    Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events    None      5    Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events    None      6    Payment made to me ducational events    None      0    Obstelin: Obstelin: Obstelin: Disposibility syndome: Diagnosis. Treatment, controversies. American Society for Clinical Laboratory Service Region VII Annual Seminar, October 20, 2020    Payment made to me Payment made to me      1    Randows, Cornell UniversityHosphalig syndome: A talle of three patients May 26, 2021    Payment made to me      2    Grand Rounds, University of New York. StomyProve, November 3, 2021    Payment made to me      1    Obstelin: Obstelin: Obstelin: American Society for Clinical Laboratory Service Region VII Annual Seminar, October 20, 2020    Payment made to me      2    Grand Rounds, University of Rewindtogy, Obstelint Remaining Synopholipid syndome. September 25, 2022    Payment made to me      3    Swanson, Martin & Bell medical expert consultancy Bendin Sumal & Ladner medical expert consultancy    Payment made to me      4    Swanson, Martin & Sell medical expert consultancy    Payment made to me      5    Swansor, Martin & Sell medical exp	2	Develties or licenses		
Member. UCB Women with Informatory Disease Advisory Board. Meeting 09/12/2020.      Payment made to me        5      Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	5	Royalles of licenses		
Member. UCB Women with Informatory Disease Advisory Board. Meeting 09/12/2020.      Payment made to me        5      Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events				
Member. UCB Women with Inflammatory Disease Advisory Board. Meeting 09/12/2020.      Payment made to me        5      Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events      None      Payment made to me        6      Payment for expert testimony      Costerica Grand Rounds, University of lowa, Obstetric antiphospholipid syndrome: Diagnosis, treatment. controversies. American Society for Clinical Laboratory Service Region VIII Annual Seminar, Cottober 20, 2020      Payment made to me        7      Payment made to me      Payment made to me        8      Advisory Bervice Region VIII Annual Seminar, Cottober 20, 2020      Payment made to me        9      Payment made to me      Payment made to me        9      Association of Idaho Rheumatologists. Obstetric antiphospholipid syndrome: A tale of three patients May 26, 2021      Payment made to me        9      Grand Rounds, Cornell University/Hospital for Special Surgery Division of Rheumatology. Obstetric antiphospholipid syndrome: A tale of three patients May 26, 2022      Payment made to me        6      Payment for expert testimony      None      Payment made to me        6      Payment for expert testimony      None      Payment made to me        6      Payment for expert testimony      None      Payment made to me        Grand Raunga, Consenial University of Con	Δ	Consulting foor	None	
lectures, presentations, speakers bureaus, manuscript writing or educational events    Grand Rounds, University of lowa, Obstetric antiphospholipid syndrome: A tale of two patients. October 27, 2020    Payment made to me      Obstetric antiphospholipid syndrome: A tale of two patients. October 27, 2020    Payment made to me      Obstetric antiphospholipid syndrome: Diagnosis, treatment, controversies. American Society for Clinical Laboratory Service Region VIII Annual Seminar, October 20, 2020    Payment made to me      December 4, 2021.    Association of Idaho Rheumatologists. Obstetric antiphospholipid syndrome. December 4, 2021.    Payment made to me      Grand Rounds, Cornell University/Hospholipid syndrome: A tale of three patients May 26, 2021    Payment made to me      Verset 4, 2021.    Grand Rounds, Cornell University/Hospholipid syndrome: A tale of three patients May 26, 2021    Payment made to me      Verset 4, 2021.    Grand Rounds, University of New York, Stonybrock, November 3, 2021    Payment made to me      Verset 4, 2021.    Grand Rounds, University of New York, Stonybrock, November 3, 2021    Payment made to me      Verset 5, 2022    Swanson, Martin & Bell medical expert consultancy    Payment made to me      Bendin Sumral 8 Ladner    Payment made to me    Payment made to me      Michigan Professional    Martinea Bell medical expert consultancy    Payment made to me      Sorand, Christerisen & Martinaeu medical expert consulta	-		Member, UCB Women with Inflammatory Disease Advisory Board. Meeting	Payment made to me
lectures, presentations, speakers bureaus, manuscript writing or educational events    Grand Rounds, University of lowa, Obstetric antiphospholipid syndrome: A tale of two patients. October 27, 2020    Payment made to me      Obstetric antiphospholipid syndrome: A tale of two patients. October 27, 2020    Payment made to me      Obstetric antiphospholipid syndrome: Diagnosis, treatment, controversies. American Society for Clinical Laboratory Service Region VIII Annual Seminar, October 20, 2020    Payment made to me      December 4, 2021.    Association of Idaho Rheumatologists. Obstetric antiphospholipid syndrome. December 4, 2021.    Payment made to me      Grand Rounds, Cornell University/Hospholipid syndrome: A tale of three patients May 26, 2021    Payment made to me      Verset 4, 2021.    Grand Rounds, Cornell University/Hospholipid syndrome: A tale of three patients May 26, 2021    Payment made to me      Verset 4, 2021.    Grand Rounds, University of New York, Stonybrock, November 3, 2021    Payment made to me      Verset 4, 2021.    Grand Rounds, University of New York, Stonybrock, November 3, 2021    Payment made to me      Verset 5, 2022    Swanson, Martin & Bell medical expert consultancy    Payment made to me      Bendin Sumral 8 Ladner    Payment made to me    Payment made to me      Michigan Professional    Martinea Bell medical expert consultancy    Payment made to me      Sorand, Christerisen & Martinaeu medical expert consulta	5	Payment or honoraria for	None	
syndrome: Diagnosis, treatment, controversies, American Society for Clinical Laboratory Service Region VIII Annual Seminar, October 20, 2020      Payment made to me        Association of Idaho Rheumatologists. Obstetric antiphospholipid syndrome. December 4, 2021.      Payment made to me        Grand Rounds, Cornell University/Hospital for Special Surgery Division of Rheumatology, Obstetric antiphospholipid syndrome: A tale of three patients May 26, 2021      Payment made to me        Grand Rounds, University of New York, Stonybrook, November 3, 2021      Payment made to me        FWGBD conference, Thrombotic antiphospholipid syndrome. September 25, 2022      Payment made to me        Sugery Division of Rheur Jong Stonybrook, November 3, 2021      Payment made to me        FWGBD conference, Thrombotic antiphospholipid syndrome. September 25, 2022      Payment made to me        Suason, Martin & Bell medical expert consultancy Bendin Sumrall & Ladner Michigan Professional Insurance Exchange medical expert consultancy      Payment made to me        Gershon, Willoughby & Getz medical expert consultancy      Payment made to me        Gershon, Willoughby & Getz medical expert consultancy      Payment made to me        Gershon, Willoughby & Getz medical expert consultancy      Payment made to me	5	lectures, presentations, speakers bureaus, manuscript writing or	Grand Rounds, University of lowa, Obstetric antiphospholipid syndrome: A tale of two patients. October 27, 2020	Payment made to me
Rheumatologists. Obstetric antiphospholipid syndrome. December 4, 2021.    Payment made to me      Grand Rounds, Cornell University/Hospital for Special Surgery Division of Rheumatology, Obstetric antiphospholipid syndrome: A tale of three patients May 26, 2021    Payment made to me      Grand Rounds, University of New York, Stonybrook, November 3, 2021    Payment made to me      FWGBD conference, Thrombotic antiphospholipid syndrome. September 25, 2022    Payment made to me      Swanson, Martin & Bell medical expert consultancy    Payment made to me      Wichigan Professional Insurance Exchange medical expert consultancy    Payment made to me      Michigan Professional Insurance Exchange medical expert consultancy    Payment made to me      Payment made to me    Stonyer consultancy Michigan Professional Insurance Exchange medical expert consultancy    Payment made to me      Snow, Christensen & Martineau medical expert consultancy    Payment made to me    Payment made to me			syndrome: Diagnosis, treatment, controversies. American Society for Clinical Laboratory Service Region VIII Annual Seminar, October 20,	Payment made to me
Image: Surgery Division of Rheumatology, Obstetric antiphospholipid syndrome: A tale of three patients May 26, 2021    Payment made to me      Image: Surgery Division of Rheumatology, Obstetric antiphospholipid syndrome: A tale of three patients May 26, 2021    Payment made to me      Image: Surgery Division of Rheumatology, Obstetric antiphospholipid syndrome: A tale of three patients May 26, 2021    Payment made to me      Image: Surgery Division of Rheumatology, Obstetric antiphospholipid syndrome: September 3, 2021    Payment made to me      Image: Surgery Division of New York, Stonybrook, November 3, 2021    Payment made to me      Image: Surgery Division of Rheumatology, Obstetric antiphospholipid syndrome. September 25, 2022    Payment made to me      Image: Surgery Division of Rheumatology, Division of New York, Stonybrook, November 3, 2021    Payment made to me      Image: Surgery Division of Rheumatology, Division of Rheumatology, Division of Surgery Division of Rheumatology,			Rheumatologists. Obstetric antiphospholipid syndrome.	Payment made to me
Grand Rounds, University of New York, Stonybrook, November 3, 2021    Payment made to me      FWGBD conference, Thrombotic antiphospholipid syndrome. September 25, 2022    Payment made to me      Payment for expert testimony   None      Bendin Sumrall & Ladner medical expert consultancy    Payment made to me      Michigan Professional Insurance Exchange medical expert consultancy    Payment made to me      Gershon, Willoughby & Getz medical expert consultancy    Payment made to me      Michigan Professional Insurance Exchange medical expert consultancy    Payment made to me      Snow, Christensen & Martineau medical expert consultancy    Payment made to me      Payment made to me    Payment consultancy      Payment made to me    Payment made to me      Michigan Professional Insurance Exchange medical expert consultancy    Payment made to me      Payment made to me    Payment made to me			University/Hospital for Special Surgery Division of Rheumatology, Obstetric antiphospholipid syndrome: A tale of three patients May 26,	Payment made to me
6    Payment for expert testimony   None      6    Payment for expert testimony   None      9   None   None      9    Swanson, Martin & Bell medical expert consultancy    Payment made to me      9    Bendin Sumrall & Ladner medical expert consultancy    Payment made to me      9    Michigan Professional Insurance Exchange medical expert consultancy    Payment made to me      9    Gershon, Willoughby & Getz medical expert consultancy    Payment made to me      9    Snow, Christensen & Martineau medical expert consultancy    Payment made to me			Grand Rounds, University of New York, Stonybrook,	Payment made to me
testimony    Swanson, Martin & Bell medical expert consultancy    Payment made to me      Bendin Sumrall & Ladner medical expert consultancy    Payment made to me      Michigan Professional Insurance Exchange medical expert consultancy    Payment made to me      Gershon, Willoughby & Getz medical expert consultancy    Payment made to me      Snow, Christensen & Martineau medical expert consultancy    Payment made to me			FWGBD conference, Thrombotic antiphospholipid syndrome. September 25,	Payment made to me
medical expert consultancy    Regiment made to me      Bendin Sumrall & Ladner    Payment made to me      medical expert consultancy    Payment made to me      Michigan Professional    Payment made to me      Insurance Exchange medical    Payment made to me      Gershon, Willoughby & Getz    Payment made to me      medical expert consultancy    Payment made to me      Snow, Christensen &    Payment made to me      Martineau medical expert consultancy    Payment made to me	6	Payment for expert		
medical expert consultancy  rayment made to me    Michigan Professional Insurance Exchange medical expert consultancy  Payment made to me    Gershon, Willoughby & Getz medical expert consultancy  Payment made to me    Snow, Christensen & Martineau medical expert consultancy  Payment made to me		testimony		Payment made to me
Michigan Professional Insurance Exchange medical expert consultancy    Payment made to me      Gershon, Willoughby & Getz medical expert consultancy    Payment made to me      Snow, Christensen & Martineau medical expert consultancy    Payment made to me				Payment made to me
medical expert consultancy  Payment made to me    Snow, Christensen & Martineau medical expert consultancy  Payment made to me			Michigan Professional Insurance Exchange medical expert consultancy	Payment made to me
Snow, Christensen & Payment made to me Martineau medical expert consultancy				Payment made to me
7  Support for attending XNone			Snow, Christensen & Martineau medical expert	Payment made to me
	7	Support for attending	XNone	

	meetings and/or travel		
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None Member, Data Safety and Monitoring Board (DSMB),Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects (NCT03750968), 2019-2022	Payment made to institution
		Member, Data Safety and Monitoring Board (DSMB), Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ) (NCT04474223), 2021-present	Payment made to me
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

Date:	_27 <sup>th</sup> November 2022
Your Name:	AURA ANDREOLI

# Manuscript Title:\_ FLUCTUATION OF ANTI-DOMAIN 1 AND ANTI-β2 GLYCOPROTEIN I ANTIBODY TITERS OVER TIME IN PATIENTS WITH PERSISTENTLY POSITIVE ANTIPHOSPHOLIPID ANTIBODIES

Manuscript number (if known): ar-22-1268

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed) Time frame: Since the initial	planning of the work
		Time frame. Since the initial	
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Werfen Group	Speaker's fees at educational meetings
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

Date:N	ovember 2	7, 2022		 	
Your Name:	Mi	chelle Petri MD N	ЛРН	 	

Manuscript Title:\_ FLUCTUATION OF ANTI-DOMAIN 1 AND ANTI-β2 GLYCOPROTEIN I ANTIBODY TITERS OVER TIME IN PATIENTS WITH PERSISTENTLY POSITIVE ANTIPHOSPHOLIPID ANTIBODIES

Manuscript number (if known): ar-22-1268

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
6	testimony	_XNone	
	testimony		
7	Support for attending	X None	
ĺ ,	meetings and/or travel		
8	Patents planned, issued or	_XNone	
	pending		
-			
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

Date:27-NOV-2022

Your Name: RICARD CERVERA

# Manuscript Title:\_ FLUCTUATION OF ANTI-DOMAIN 1 AND ANTI-β2 GLYCOPROTEIN I ANTIBODY TITERS OVER TIME IN PATIENTS WITH PERSISTENTLY POSITIVE ANTIPHOSPHOLIPID ANTIBODIES

Manuscript number (if known): ar-22-1268

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed) Time (normal Circle the initial	
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	None	
Ū	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Date:	11/26/22	2

Your Name:\_\_\_\_Jason S. Knight\_\_

# Manuscript Title:\_ FLUCTUATION OF ANTI-DOMAIN 1 AND ANTI-β2 GLYCOPROTEIN I ANTIBODY TITERS OVER TIME IN PATIENTS WITH PERSISTENTLY POSITIVE ANTIPHOSPHOLIPID ANTIBODIES

Manuscript number (if known): ar-22-1268

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
9	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Date:\_\_\_\_\_November 29, 2022\_\_\_\_\_

Your Name:\_\_\_\_\_\_Rohan Willis\_\_\_\_\_\_

### Manuscript Title:\_ FLUCTUATION OF ANTI-DOMAIN 1 AND ANTI-β2 GLYCOPROTEIN I ANTIBODY TITERS OVER TIME IN PATIENTS WITH PERSISTENTLY POSITIVE ANTIPHOSPHOLIPID ANTIBODIES

Manuscript number (if known): ar-22-1268

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	
			20
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastNone	36 months
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	
0	testimony		
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	•	Nege	
10	Leadership or fiduciary role in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		

Date:	27 <sup>th</sup> November 2022
Your Name	Maria Efthymiou

# Manuscript Title:\_ FLUCTUATION OF ANTI-DOMAIN 1 AND ANTI-β2 GLYCOPROTEIN I ANTIBODY TITERS OVER TIME IN PATIENTS WITH PERSISTENTLY POSITIVE ANTIPHOSPHOLIPID ANTIBODIES

Manuscript number (if known): ar-22-1268

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	Alexion	
		Pharmaceutical	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	incerings and/or traver		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
5	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Descist of any in the	News	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Date: 29 November 2022

Your Name: Hannah Cohen

# Manuscript Title:\_ FLUCTUATION OF ANTI-DOMAIN 1 AND ANTI-β2 GLYCOPROTEIN I ANTIBODY TITERS OVER TIME IN PATIENTS WITH PERSISTENTLY POSITIVE ANTIPHOSPHOLIPID ANTIBODIES

Manuscript number (if known): ar-22-1268

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	Springer Nature: Royalties as editor of 'Disorders of	

		Thrombosis and Hemostasis in Pregnancy' 2nd Edition	
4	Consulting fees	UCB Biopharma	paid to University College London Hospitals (UCLH) Charity
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Honorarium for lecture from Technoclone	paid to UCLH Charity
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Advisory Board Member (Roche)	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Chair, Subcommittee on Lupus anticoagulant/ Antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis Scientific and Standardisation Committee	unpaid
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	Werfen	Provided APS Action with kits for testing of aPL through an unrestricted grant – there was no involvement of Werfen in the design of this study, analysis of the data and/or preparation of this manuscript
13	Other financial or non- financial interests	None	

Date:\_\_\_11/25/22\_\_

Your Name:\_\_\_\_Doruk Erkan\_

Manuscript Title: FLUCTUATION OF ANTI-DOMAIN 1 AND ANTI-β2 GLYCOPROTEIN I ANTIBODY TITERS OVER TIME IN PATIENTS WITH PERSISTENTLY POSITIVE ANTIPHOSPHOLIPID ANTIBODIES

Manuscript number (if known): ar-22-1268

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	ACR/EULAR NIH/NIAID GSK Exagen	Institution Institution Institution Institution
3	Royalties or licenses	Up-To-Date	Me

4	Consulting fees	Chugai	Me
5	Payment or honoraria for	GSK	Me
5	lectures, presentations, speakers bureaus, manuscript writing or educational events	Aurinia	Me
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	Wefen	Provided APS Action with kits for testing of aPL through an unrestricted grant – there was no involvement of Werfen in the design of this study, analysis of the data and/or preparation of this manuscript
13	Other financial or non- financial interests	None	

Date: 28/11/2022

Your Name: Maria Laura Bertolaccini

# Manuscript Title: FLUCTUATION OF ANTI-DOMAIN 1 AND ANTI-β2 GLYCOPROTEIN I ANTIBODY TITERS OVER TIME IN PATIENTS WITH PERSISTENTLY POSITIVE ANTIPHOSPHOLIPID ANTIBODIES

Manuscript number (if known): ar-22-1268

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
			plaining of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
/	meetings and/or travel		
	meetings and/or traver		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
10	Advisory Board		
10		None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	Werfen	Provided APS Action with kits for testing of aPL through
	materials, drugs, medical		an unrestricted grant – there was no involvement of
	writing, gifts or other		Werfen in the design of this study, analysis of the data
	services		and/or preparation of this manuscript
13	Other financial or non-	None	
15	financial interests		